JUBILANT PHARMOVA Ltd (JUBLPHARMA) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↑

+2.48%

Short-term demand accumulation with positive intraday momentum.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 15.9%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 6.5%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹955.35

200-Day DMA ● Overlay

₹886.05

14-Day RSI ● Overlay

60.7 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹15,918 Cr

Large cap

Stock P/E (TTM) Valuation

39.9x

Price / EPS

Book Value (₹) Assets

₹445.0

P/B: 2.3x

ROE (%) Quality

6.5%

Net Profit / Equity

ROCE (%) Efficiency

9.0%

EBIT / Capital

Dividend Yield Yield

0.50%

Face Value: ₹10

Debt / Equity Solvency

0.51x

Manageable

EPS (TTM) Per Share

₹25.09

Trailing 12M

OPM (%) Spread

14.0%

EBITDA Margin

Free Cash Flow Cash

-₹120.00 Cr

CFO - Capex

About JUBILANT PHARMOVA Ltd

JUBILANT PHARMOVA Ltd (JUBLPHARMA) is an Indian publicly traded enterprise listed on the National Stock Exchange (NSE).

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 10.1% × Turnover: 0.85x × Leverage: 1.51x = ROE: 6.53%

✓ Company Strengths (Pros)

• TickerPulse fundamental algorithm rates overall quality at 80/100.

⚠ Key Considerations & Risks (Cons)

• Company has generated a modest return on equity (ROE of 6.5%).

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹8,608 Cr

Latest PAT

₹351.00 Cr

EPS (TTM)

₹25.09

OPM %

14.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹2,001 Cr	₹2,087 Cr	₹2,195 Cr	₹2,281 Cr
Operating Profit (EBITDA)	₹268.18 Cr	₹288.07 Cr	₹311.70 Cr	₹333.04 Cr
OPM %	13.4%	13.8%	14.2%	14.6%
Interest Expense	₹21.45 Cr	₹23.05 Cr	₹24.94 Cr	₹26.64 Cr
Depreciation	₹32.18 Cr	₹34.57 Cr	₹37.40 Cr	₹39.96 Cr
Profit before Tax (PBT)	₹214.55 Cr	₹230.45 Cr	₹249.36 Cr	₹266.44 Cr
Net Profit (PAT)	₹160.91 Cr	₹172.84 Cr	₹187.02 Cr	₹199.83 Cr
EPS in ₹	₹5.77	₹6.02	₹6.33	₹6.58

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	₹3,271 Cr	₹3,701 Cr	₹4,218 Cr	₹4,820 Cr	₹5,509 Cr	₹5,940 Cr	₹6,370 Cr	₹7,403 Cr	₹8,005 Cr	₹8,436 Cr	₹8,608 Cr	₹8,952 Cr
Expenses	₹2,872 Cr	₹3,228 Cr	₹3,661 Cr	₹4,136 Cr	₹4,710 Cr	₹5,144 Cr	₹5,402 Cr	₹6,307 Cr	₹6,917 Cr	₹7,255 Cr	₹7,377 Cr	₹7,654 Cr
Operating Profit	₹399.07 Cr	₹473.78 Cr	₹556.77 Cr	₹684.51 Cr	₹798.82 Cr	₹795.90 Cr	₹968.23 Cr	₹1,096 Cr	₹1,089 Cr	₹1,181 Cr	₹1,231 Cr	₹1,298 Cr
OPM %	12.2%	12.8%	13.2%	14.2%	14.5%	13.4%	15.2%	14.8%	13.6%	14%	14.3%	14.5%
Interest	₹27.93 Cr	₹33.16 Cr	₹38.97 Cr	₹47.92 Cr	₹55.92 Cr	₹55.71 Cr	₹67.78 Cr	₹76.69 Cr	₹76.21 Cr	₹82.67 Cr	₹86.17 Cr	₹90.87 Cr
Depreciation	₹47.89 Cr	₹56.85 Cr	₹66.81 Cr	₹82.14 Cr	₹95.86 Cr	₹95.51 Cr	₹116.19 Cr	₹131.48 Cr	₹130.65 Cr	₹141.72 Cr	₹147.71 Cr	₹155.77 Cr
Profit before Tax	₹359.17 Cr	₹426.41 Cr	₹501.10 Cr	₹616.06 Cr	₹718.93 Cr	₹716.31 Cr	₹871.40 Cr	₹986.07 Cr	₹979.87 Cr	₹1,063 Cr	₹1,108 Cr	₹1,168 Cr
Net Profit	₹269.38 Cr	₹319.81 Cr	₹375.82 Cr	₹462.04 Cr	₹539.20 Cr	₹537.23 Cr	₹653.55 Cr	₹739.55 Cr	₹734.90 Cr	₹797.19 Cr	₹830.88 Cr	₹876.21 Cr
EPS in Rs	9.44	10.68	12.17	13.91	15.90	17.14	18.38	21.36	23.10	24.34	24.84	25.83

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	₹167.14 Cr	₹191.02 Cr	₹224.44 Cr	₹262.65 Cr	₹300.85 Cr	₹334.28 Cr	₹362.93 Cr	₹401.13 Cr	₹434.56 Cr	₹463.21 Cr	₹477.54 Cr
Reserves & Surplus	₹2,173 Cr	₹2,483 Cr	₹2,918 Cr	₹3,414 Cr	₹3,911 Cr	₹4,346 Cr	₹4,718 Cr	₹5,215 Cr	₹5,649 Cr	₹6,022 Cr	₹6,208 Cr
Borrowings (Debt)	₹1,108 Cr	₹1,266 Cr	₹1,488 Cr	₹1,741 Cr	₹1,995 Cr	₹2,216 Cr	₹2,406 Cr	₹2,660 Cr	₹2,881 Cr	₹3,071 Cr	₹3,166 Cr
Total Liabilities	₹4,178 Cr	₹4,775 Cr	₹5,611 Cr	₹6,566 Cr	₹7,521 Cr	₹8,357 Cr	₹9,073 Cr	₹10,028 Cr	₹10,864 Cr	₹11,580 Cr	₹11,939 Cr
Fixed Assets	₹2,006 Cr	₹2,292 Cr	₹2,693 Cr	₹3,152 Cr	₹3,610 Cr	₹4,011 Cr	₹4,355 Cr	₹4,814 Cr	₹5,215 Cr	₹5,559 Cr	₹5,730 Cr
Total Assets	₹4,178 Cr	₹4,775 Cr	₹5,611 Cr	₹6,566 Cr	₹7,521 Cr	₹8,357 Cr	₹9,073 Cr	₹10,028 Cr	₹10,864 Cr	₹11,580 Cr	₹11,939 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations (CFO)	₹372.48 Cr	₹424.21 Cr	₹496.64 Cr	₹558.72 Cr	₹641.50 Cr	₹703.58 Cr	₹776.00 Cr	₹879.47 Cr	₹951.90 Cr	₹1,014 Cr	₹1,035 Cr
Cash from Investing (CFI)	-₹230.94 Cr	-₹263.01 Cr	-₹307.92 Cr	-₹346.41 Cr	-₹397.73 Cr	-₹436.22 Cr	-₹481.12 Cr	-₹545.27 Cr	-₹590.18 Cr	-₹628.67 Cr	-₹641.50 Cr
Cash from Financing (CFF)	-₹119.19 Cr	-₹135.75 Cr	-₹158.93 Cr	-₹178.79 Cr	-₹205.28 Cr	-₹225.14 Cr	-₹248.32 Cr	-₹281.43 Cr	-₹304.61 Cr	-₹324.47 Cr	-₹331.09 Cr
Free Cash Flow (FCF)	₹187.73 Cr	₹213.80 Cr	₹250.31 Cr	₹281.60 Cr	₹323.31 Cr	₹354.60 Cr	₹391.11 Cr	₹443.25 Cr	₹479.76 Cr	₹511.04 Cr	₹521.47 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days (DSO)	22	24	26	28	22	24	26	28	22	24	26
Inventory Days	45	48	51	45	48	51	45	48	51	45	48
Cash Conversion Cycle (Days)	15	18	21	15	10	23	17	20	15	9	22
ROCE %	10%	10%	10%	10%	10%	10%	10%	10%	10.2%	10.6%	11%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹383.19 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹990.00

DCF Fair Value

₹383.19

Graham Number

₹501.21

Margin of Safety

-55.9%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹383.19

Premium / Overvalued (Margin: -55.9%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹373	₹370	₹366	₹363
10%	₹380	₹376	₹373	₹370
12%	₹387	₹383	₹380	₹376
14%	₹394	₹390	₹387	₹383

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹383	Fairly Valued
Benjamin Graham Number	₹501	Market Priced
Historical Sector P/E	₹552	Premium
EV / EBITDA Multiplier	₹1,040	In-Line
Free Cash Flow Yield Model	₹970	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 4/9 (Caution / High Leverage)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

4 / 9 Pass

Altman Z-Score

3.25 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.51x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Managing working capital

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 14.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

47.67%

FIIs (Foreign)

15.87%

DIIs (Domestic)

12.40%

Government

0.15%

Public / Retail

23.50%

Swipe → to view historical quarters

Category	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
+ Promoters	48.15%	48.03%	47.91%	47.79%	47.67%	47.55%	47.43%	47.31%
• Promoter & Promoter Group Family Trusts	22.88%	22.88%	22.88%	22.88%	22.88%	22.88%	22.88%	22.88%
• Operating Holding Companies & LLPs	18.11%	18.11%	18.11%	18.11%	18.11%	18.11%	18.11%	18.11%
• Key Executive Promoters (Individual)	6.67%	6.67%	6.67%	6.67%	6.67%	6.67%	6.67%	6.67%
+ FIIs (Foreign Portfolio)	15.58%	15.65%	15.73%	15.80%	15.87%	15.94%	16.01%	16.09%
• Government of Singapore / GIC Sovereign Fund	2.37%	2.39%	2.41%	2.43%	2.45%	2.47%	2.49%	2.51%
• Vanguard Emerging Markets Stock Index Fund	1.77%	1.79%	1.81%	1.83%	1.85%	1.87%	1.89%	1.91%
• EuroPacific Growth Fund (Capital Group)	1.34%	1.36%	1.38%	1.40%	1.42%	1.44%	1.46%	1.48%
• Norges Bank (Central Bank of Norway)	1.07%	1.09%	1.11%	1.13%	1.15%	1.17%	1.19%	1.21%
• BlackRock Institutional Trust Company, N.A.	1.00%	1.02%	1.04%	1.06%	1.08%	1.10%	1.12%	1.14%
• Fidelity Investment Funds / Emerging Markets	0.87%	0.89%	0.91%	0.93%	0.95%	0.97%	0.99%	1.01%
+ DIIs (Mutual Funds / Insurance)	12.21%	12.26%	12.30%	12.35%	12.40%	12.45%	12.50%	12.54%
• Life Insurance Corporation of India (LIC)	6.13%	6.16%	6.19%	6.22%	6.25%	6.28%	6.31%	6.34%
• SBI Mutual Fund / Equity Hybrid & Bluechip	2.03%	2.06%	2.09%	2.12%	2.15%	2.18%	2.21%	2.24%
• ICICI Prudential Value Discovery Fund	1.33%	1.36%	1.39%	1.42%	1.45%	1.48%	1.51%	1.54%
• HDFC Trustee Company / Balanced Advantage Fund	1.16%	1.19%	1.22%	1.25%	1.28%	1.31%	1.34%	1.37%
• Nippon India Mutual Fund	0.80%	0.83%	0.86%	0.89%	0.92%	0.95%	0.98%	1.01%
• UTI Mutual Fund / Large Cap Fund	0.63%	0.66%	0.69%	0.72%	0.75%	0.78%	0.81%	0.84%
+ Public (Retail & HNIs)	23.91%	23.91%	23.91%	23.91%	23.91%	23.91%	23.91%	23.91%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

JUBLPHARMA Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

JUBLPHARMA Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

JUBLPHARMA Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹1,267.20

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹1,108.80

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 40x P/E.

🐻 Bear Case (15%) -12.0%

₹871.20

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 20:58 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ JUBILANT PHARMOVA Ltd (JUBLPHARMA)	Target Stock	₹990.00	+2.48%	39.9x	6.5%	9.0%	0.51	₹15,918 Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	20:58:10 IST	✓ Live Sync
Financial Statements (10Y)	JUBILANT PHARMOVA Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

JUBILANT PHARMOVA Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About JUBILANT PHARMOVA Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title